purported action of KU-55933 in reducing metformin-stimulated phosphorylation of AMPK shown in the previous study occurred as a result of inhibition of metformin uptake via OCT1 rather than through a direct effect on metformininduced activation of AMPK.
We examined the inhibitory effect of KU-55933 (Tocris Bioscience) on [ 14 C]-metformin (Moravek) uptake in H4IIE rat hepatoma cells (Fig. 1a) and in HEK293 cells stably expressing OCT1 (Fig. 1b) . In parallel, we examined the effect of KU-55933 on metformin-induced AMPK activation in H4IIE cells ( Supplementary  Fig. 1 ). In the metformin uptake assays, we observed that KU-55933 blocked more than 70% of [ 14 C]-metformin uptake in H4IIE cells under the conditions used in the previous study 1 (Fig. 1a) . To directly establish that KU-55933 is an inhibitor of OCT1, we also determined its effect on metformin uptake in HEK293 cells stably expressing OCT1. KU-55933 (10 µM) significantly and substantially inhibited [ 14 C]-metformin uptake in OCT1-expressing cells (Fig. 1b) . Although results were obtained following 30 min of incubation with KU-55933 and an additional 1 h of exposure to metformin, inhibitory effects of KU-55933 on metformin uptake also occurred at earlier times. However, greater degrees of inhibition were observed at later time points (Supplementary Fig. 2 ). Consistent with known expression patterns of organic cation transporters in the liver, RT-PCR experiments showed that mRNA levels of rat Slc22a1 (the official symbol for Oct1) were highest in H4IIE cells in comparison to the other organic cation transporters (Slc22a2, Slc22a3, Slc47a1 and Slc47a2) (data not All the compounds except paraaminohippuric acid (PAH; a negative control) significantly inhibited metformin uptake (***P < 0.001, **P < 0.01, *P < 0.05; unpaired Student's t test) compared to cells preincubated with DMSO alone. All data are expressed as mean ± s.d. from two independent uptake experiments. HEK293 cells stably expressing human OCT1 showed greater OCT1 expression on the plasma membrane compared to cells expressing empty vector 6 . 
To the Editor:
In a recently reported genome-wide association study, the rs11212617 SNP was determined to be associated with the efficacy of metformin treatment in type 2 diabetes 1 . One of the genes at this locus is ATM, which is mutated in ataxia telangiectasia, a neurodegenerative disease associated with predisposition to cancer 2 . One of the targets of metformin action is the AMP-activated protein kinase (AMPK) 3 , a protein kinase that has a key role in maintaining energy homeostasis 4 . The authors of the previous study showed that activation of AMPK by metformin was reduced by treatment with an ATM inhibitor, KU-55933, and concluded that ATM has a direct role in the activation of AMPK by metformin 1 . Their study raises a number of exciting possibilities linking metabolism and cancer.
We were interested in exploring the mechanism by which ATM is involved in AMPK activation. In primary mouse hepatocytes (Supplementary Methods), metformin, although causing a robust activation of AMPK (Fig. 1a) , had no effect on the phosphorylation of H2AX, a downstream target of ATM. In contrast, exposure to UV light increased phosphorylation of H2AX but had no effect on AMPK activity (Fig. 1a) . Phosphorylation of H2AX in response to UV light was reduced by pretreatment of cells with KU-55933 or with caffeine, a nonselective inhibitor of ATM 5 . KU-55933 but not caffeine reduced AMPK activation by metformin (Fig. 1a) . These results suggest that ATM is not directly involved in AMPK activation by metformin but that KU-55933 reduces AMPK activity in an ATM-independent manner. We were unable to find any direct effect of KU-55933 on the activity of either AMPK or LKB1 (the main upstream AMPK kinase in liver 6 ) or on the dephosphorylation of AMPK in vitro (Supplementary Fig. 1) .
Metformin uptake is mediated by the organic cation transporter (OCT) family and, in mouse hepatocytes, deletion of the Slc22a1 gene encoding Oct1 reduces AMPK activation by metformin 7 . We therefore examined the effect of KU-55933 on metformin uptake in primary mouse hepatocytes. KU-55933 significantly (P < 0.001) reduced metformin content in hepatocytes (Fig. 1b) , providing an explanation for its effect on AMPK activation by metformin (Fig. 1a) . Additional studies showed that the intracellular accumulation of metformin in hepatocytes was inhibited cells (Supplementary Fig. 3b,c) . These results suggest that the effect of KU-55933 on metformin uptake via Oct1 is independent of Atm and that Atm does not have a detectable effect on Oct1 activity.
In summary, we were interested to see this first GWAS on metformin response, which reported an association of variants with genome-wide significance at the locus near ATM. Our data suggest that further studies are needed to establish whether ATM or another gene in the ATM locus is the causative gene and, if so, to determine the mechanism by which it modulates the response to metformin. Although metformin has been on the market for many years and is a first-line therapy for type 2 diabetes, the mechanisms of metformin's pharmacologic action, including its target(s), remain controversial [10] [11] . GWAS can suggest important mechanistic information, and it is critical to perform additional studies to identify and refute or establish causal genes that have a role in the anti-diabetic effects of metformin. shown). Taken together, these data and the data in Figure 1 suggest that KU-55933 inhibits metformin uptake in H4IIE cells via inhibition of OCT1.
Similar to the authors' findings, we also observed that KU-55933 significantly attenuated metformin-stimulated phosphorylation of AMPK ( Supplementary  Fig. 1 ). Known OCT inhibitors from diverse chemical and pharmacologic classes, cimetidine, imatinib and verapamil [6] [7] [8] , reduced metformin uptake in both H4IIE and OCT1-transfected cells (Fig. 1a,b) and, in parallel, reduced metformin-induced AMPK phosphorylation in H4IIE cells (Supplementary Fig. 1a,b) . These results are consistent with our previous observations with other OCT inhibitors, verapamil and cimetidine, in mouse and human cells 6, 7 . Given these results, we suggest that KU-55933 attenuates metformin-induced AMPK phosphorylation as a result of its inhibition of metformin uptake into the cells. Our studies in the cell lines suggest that inhibition of OCT1-mediated metformin uptake is the mechanism by which KU-55933 caused inhibition of metforminstimulated AMPK phosphorylation in H4IIE cells. Of note, at baseline, KU-55933 enhanced the phosphorylation of AMPK in H4IIE cells (Supplementary Fig. 1a,b) , perhaps reflecting some nonspecific effect. We noted a similar enhancement in HEK293 cells and mouse fibroblasts exposed to KU-55933 but detected no enhancement in primary hepatocytes from mice (data not shown). It is known that the ATM kinase is activated after the introduction of DNA double-strand breaks 9 ; therefore, the activity of ATM is likely to be low in unperturbed cells, such as H4IIE cells.
Another interpretation of the cellular assays described in the previous study, which would be consistent with our studies showing that KU-55933 reduces metformin uptake, would be that KU-55933 inhibited ATM, which in turn reduced OCT1 activity. To determine whether ATM affects the uptake function of OCT1, we transiently transfected Atm +/+ (A29) and Atm -/-(A38) mouse embryonic fibroblasts with a construct encoding mouse Oct1. The results showed that the uptake of metformin was greater in the Oct1-transfected A29 and A38 cells relative to cells transfected with empty vector and that there was no difference in metformin uptake between the two cell lines (Supplementary Fig. 3a) . In the presence of KU-55933, Oct1-transfected A29 and A38 cells showed significantly lower metformin uptake compared to untreated npg
